Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results

Key Points

• Monte Rosa Therapeutics missed quarterly expectations: It reported a loss of $0.43 per share versus the $0.38 consensus estimate, while revenue of $8.97 million fell short of expectations of $12.91 million. The company posted a negative net margin of 560.85%.
• Analysts remain broadly positive despite lower price targets: Seven analysts rate the stock a Buy, one rates it Hold and one rates it Sell, resulting in a “Moderate Buy” consensus and an average price target of $28.50. Several firms recently reduced their targets to between $27 and $28.
• Shares rose modestly after the results but remain volatile: GLUE traded up 1.1% to $15.88, compared with a 52-week range of $4.12 to $25.77. Insiders sold 81,778 shares worth about $1.77 million over the past 90 days, while institutional investors own nearly 80% of the stock.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) announced its earnings results on Thursday. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05), FiscalAI reports. The firm had revenue of $8.97 million during the quarter, compared to analysts' expectations of $12.91 million. Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 48.30%.

Monte Rosa Therapeutics Stock Up 1.1%

Shares of GLUE stock traded up $0.17 on Friday, hitting $15.88. The stock had a trading volume of 1,031,388 shares, compared to its average volume of 1,631,805. Monte Rosa Therapeutics has a one year low of $4.12 and a one year high of $25.77. The business has a 50 day moving average price of $20.53 and a 200 day moving average price of $19.35. The company has a market cap of $1.34 billion, a PE ratio of -9.02 and a beta of 1.59.

Analyst Ratings Changes

GLUE has been the subject of a number of recent analyst reports. Weiss Ratings raised shares of Monte Rosa Therapeutics from a "sell (d)" rating to a "sell (d+)" rating in a research note on Tuesday, July 28th. Jefferies Financial Group reissued a "buy" rating on shares of Monte Rosa Therapeutics in a research report on Monday, July 27th. Wells Fargo & Company decreased their price objective on shares of Monte Rosa Therapeutics from $29.00 to $27.00 and set an "overweight" rating for the company in a research note on Friday. Guggenheim dropped their target price on Monte Rosa Therapeutics from $35.00 to $28.00 and set a "buy" rating for the company in a research report on Friday. Finally, Wedbush cut their target price on Monte Rosa Therapeutics from $37.00 to $27.00 and set an "outperform" rating on the stock in a research note on Monday, August 3rd. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $28.50.

Insider Buying and Selling at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, COO Jennifer Champoux sold 2,176 shares of the firm's stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $19.00, for a total transaction of $41,344.00. Following the transaction, the chief operating officer owned 62,371 shares of the company's stock, valued at approximately $1,185,049. This trade represents a 3.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Anthony M. Manning sold 10,000 shares of the company's stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $23.11, for a total transaction of $231,100.00. Following the completion of the sale, the director directly owned 10,000 shares of the company's stock, valued at $231,100. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 81,778 shares of company stock valued at $1,768,581 in the last 90 days. Insiders own 6.40% of the company's stock.

Institutional Trading of Monte Rosa Therapeutics

Hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC purchased a new stake in shares of Monte Rosa Therapeutics during the 1st quarter worth $1,065,000. Goldman Sachs Group Inc. boosted its position in Monte Rosa Therapeutics by 122.7% during the first quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company's stock valued at $1,652,000 after purchasing an additional 196,238 shares in the last quarter. Acadian Asset Management LLC purchased a new position in Monte Rosa Therapeutics in the first quarter valued at about $76,000. Geode Capital Management LLC grew its stake in Monte Rosa Therapeutics by 12.0% in the second quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company's stock valued at $5,071,000 after purchasing an additional 120,098 shares during the last quarter. Finally, American Century Companies Inc. raised its holdings in Monte Rosa Therapeutics by 301.4% in the second quarter. American Century Companies Inc. now owns 403,045 shares of the company's stock worth $1,818,000 after purchasing an additional 302,639 shares in the last quarter. Hedge funds and other institutional investors own 79.96% of the company's stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company's main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source